TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ ...
In the second part of this series, we show how frontline medics are fighting for a future where routine infections do not ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...
Acute kidney injury (AKI) is among the most common organ failures observed in the hospital and can irrevocably alter the ...
Q: I have had a UTI several times and know the symptoms. This last time, when I went to urgent care, they said they needed a urine culture before they could treat me. It was another day of being ...
RIT medical illustration alumnus Erica McCarthy is president of Bloom Medical Simulation, which invented a training tool for ...
A transgender gang forcibly subjected a student to gender reassignment surgery, extorted money, and filmed obscene acts using ...
The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback